Pacira BioSciences Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pacira Pharma (PCRX) Misses Q1 EPS by 19c
May 4, 2022 8:07 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.64, $0.19 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $158 million versus the consensus estimate of $159.34 million.
Financial Guidance:
The companys product sales continue to be impacted by COVID-19, which has caused... More
